Vita Life Sciences Ltd
ASX:VLS
Vita Life Sciences Ltd
ASX:VLS
Price:
2.6
AUD
Market Closed
Market Cap:
AU$142.1m
Relative Value
The Relative Value of one
VLS
stock under the Base Case scenario is
5.18
AUD.
Compared to the current market price of 2.6 AUD,
Vita Life Sciences Ltd
is
Undervalued by 50%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
VLS
Relative Value
Base Case
5.18
AUD
Undervaluation 50%
Multiples Across Competitors
VLS Competitors Multiples
Vita Life Sciences Ltd Competitors
Vita Life Sciences Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| AU |
|
Vita Life Sciences Ltd
ASX:VLS
|
145.4m AUD | 1.7 | 15.6 | 9.2 | 9.2 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
967.2B USD | 14.8 | 46.6 | 31.4 | 33.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
579.1B USD | 6.1 | 21.6 | 15 | 18.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
281.2B CHF | 4.6 | 29.9 | 12.6 | 14.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
228.3B GBP | 5.5 | 33.7 | 16 | 23.5 | |
| CH |
|
Novartis AG
SIX:NOVN
|
235.6B CHF | 5.4 | 21.7 | 13.4 | 17.2 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
294.9B USD | 4.5 | 16.2 | 10.1 | 11.8 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 333.1 | 835.4 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK | 4.4 | 13.2 | 9.7 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
158.8B USD | 2.5 | 20.3 | 7.5 | 10.1 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
123.9B USD | 2.5 | 17.4 | 6.8 | 8.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
